AGIOS PHARMACEUTICALS, INC. Reimbursement Revenue (Deprecated 2018-01-31)
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Reimbursement Revenue (Deprecated 2018-01-31) of $33.10 million for the 3-month period ending 2015-03-31, per its 10-Q filed 2015-05-11.
Discontinued › Income Statement › Other Income
us-gaap:ReimbursementRevenue · last filed 2015-05-11
- AGIOS PHARMACEUTICALS, INC. reimbursement revenue (deprecated 2018-01-31) for the quarter ending 2015-03-31 was $33.10M.
- AGIOS PHARMACEUTICALS, INC. reimbursement revenue (deprecated 2018-01-31) for fiscal 2014 was $26.60M.
| Period end | Reimbursement Revenue (Deprecated 2018-01-31) 3 month | Reimbursement Revenue (Deprecated 2018-01-31) 12 month |
|---|---|---|
| 2015-03-31 | $33.10M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $26.60M 10-K · filed 2015-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |